Actively Recruiting

All Genders
Healthy Volunteers
ID05881226

Application of Biomarkers in Neurological Diseases

Led by Yi Yang · Updated on 2024-03-01

3000

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to explore the predictive and diagnostic roles of biomarkers in patients with neurological diseases. It focuses on using proteomics and metabolomics technologies to study brain tissue, plasma, and cerebrospinal fluid to identify potential new biomarkers. The study seeks to better understand biomarker expression in healthy individuals compared to those with neurological conditions and to address unresolved challenges in this early-stage research. Patients admitted to hospital or emergency departments with neurological diseases will be observed. Clinical data, laboratory data, imaging data, and blood and tissue samples will be collected at baseline and during follow-up at various time points in acute and chronic phases. This observational approach does not involve experimental treatments but gathers comprehensive information to support biomarker research. Participants will be monitored through clinical evaluations including a modified Rankin Scale score at 90 days. The study involves consented collection of samples without affecting patient diagnosis or treatment. Data will help researchers assess biomarker characteristics and their relation to disease progression and outcomes. The study is planned to continue until December 2031, allowing long-term follow-up and analysis.

CONDITIONS

Brief Title

Application of Biomarkers in Neurological Diseases

Who Can Participate

All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with neurological diseases
  • Subjects or legal agents agree to participate in the study and sign the informed consent.
Not Eligible

You will not qualify if you...

  • Participating in other clinical investigators
  • Unwilling to be followed up or poor treatment compliance
  • Other conditions considered unsuitable for inclusion by the researchers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to 3 months

Participants who undergo routine care are observed with collection of clinical data, laboratory data, imaging data, and biological samples at different time points in the acute and chronic phases.

Multiple visits depending on acute and chronic phase assessments

Trial Site Locations

Total: 1 location

1

First Hospital of Jilin University

Changchun, Jilin, China, 130000

Actively Recruiting

Loading map...

Research Team

Y

Yi YY Yang, Ph.D.

Z

Zhen-Ni GZ GUO, M.D.

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Adebrelimab with or Without Induction Chemotherapy Followed ...

Esophageal Squamous Cell Carcinoma

Actively Recruiting

1 location

Artificial Intelligence-assisted CT for Risk Stratification ...

Coronary Artery Disease (CAD)

Actively Recruiting

1 location

Biomarker-based Assessment of Cerebral Small Vessel Disease ...

Cerebral Small Vessel Disease

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here